Moneal Shah, MD
Cardiovascular Disease · Pittsburgh, PANPI 1609092691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,084 of the $90,422 with a category attached, or 63.1%. Heartflow, Inc. accounts for 92.5% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $62,069, more than ten times the $196 reported in 2019. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $262.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$84K
- Amgen$1K
- E.r. Squibb & Sons, L.L.C.$795
- Novartis$436
- Medtronic$432
- Pfizer$417
- plus $3K from 26 others
Across 10 payments — averaging $3990.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$40K
What the payments were for
- Consulting fees$14,48316%
- Speaking & faculty fees$57,08463%
- Travel & lodging$9,64411%
- Food & beverage$9,21110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 82 | $83,682 |
| Amgen | 51 | $1,296 |
| E.r. Squibb & Sons, L.L.C. | 41 | $795 |
| Novartis | 25 | $436 |
| Medtronic | 6 | $432 |
| Pfizer | 25 | $417 |
| Johnson & Johnson | 19 | $395 |
| Boehringer Ingelheim | 11 | $391 |
| AstraZeneca | 22 | $376 |
| Abbott | 4 | $363 |
| Edwards Lifesciences | 3 | $226 |
| Impulse Dynamics (USA) Inc. | 5 | $221 |
| Cardiac Dimensions, Inc. | 1 | $172 |
| Boston Scientific | 3 | $153 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $153 |
| Kiniksa Pharmaceuticals, Ltd. | 9 | $143 |
| Novo Nordisk | 6 | $126 |
| Cardiovascular Systems Inc. | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $93 |
| Kestra Medical Technology Services, Inc. | 3 | $76 |
| Bracco Diagnostics Inc. | 3 | $68 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Merck | 2 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Cvrx, Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $18 |
| Bayer | 1 | $16 |
| Angiodynamics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$82,072
- Repatha$365
- COREVALVE EVOLUT R$327
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$182
- MitraClip$162
- MitraClip System$157
- Diamondback Coronary$121
- ELIQUIS$121
- JARDIANCE$121
- XARELTO$116
How this compares
$90,422 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $160,620 |
| EntrestoSacubitril/Valsartan | 72 | $76,126 |
| JardianceEmpagliflozin | 54 | $62,741 |
| XareltoRivaroxaban | 41 | $38,643 |
| Repatha SureclickEvolocumab | 50 | $31,467 |
| Ranolazine ErRanolazine | 53 | $5,060 |
| BrilintaTicagrelor | 11 | $4,940 |
| Atorvastatin Calcium | 258 | $3,079 |
| Ezetimibe | 139 | $2,360 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 38 | $2,345 |
| Rosuvastatin Calcium | 133 | $1,636 |
| Metoprolol Succinate | 81 | $1,403 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 77 | $1,000 |
| Flecainide Acetate | 12 | $737 |
| Amlodipine Besylate | 152 | $667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $417 | $160,620136 claims |
| NovartisEntresto | $436 | $76,12672 claims |
| Boehringer IngelheimJardiance | $391 | $62,74154 claims |
| Johnson & JohnsonXarelto | $395 | $38,64341 claims |
| AstraZenecaBrilinta | $376 | $4,94011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Pittsburgh
- George GabrielPittsburgh$563K
- Mark GreathousePittsburgh$243K
- Brian HenryPittsburgh$224K
- Kent VolosinPittsburgh$190K
- Victor FarahPittsburgh$98K
- Stephen ChanPittsburgh$70K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.